Does CD30 loss preclude the diagnosis of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma? Insights from a rare case
Article History
-
Received: ,
Accepted: ,
Abstract
CD30 positivity serves as a critical diagnostic hallmark for anaplastic lymphoma kinase positive anaplastic large cell lymphoma (ALK+ ALCL); however, rare cases with partial or complete loss of CD30 expression present diagnostic challenges. We report a unique case with two morphologically and immunophenotypically distinct subpopulations within the same tumor: A typical CD30-positive component and a CD30-negative counterpart. Comparative genetic analysis revealed overlapping but divergent molecular features, including nucleophosmin 1-ALK (NPM1-ALK) fusion, notch receptor 1 mutations, and differential gene amplifications involving MYC proto-oncogene and BCL2-like 1. These findings offer insights into the regulatory mechanisms of CD30 and highlight that loss of CD30 expression alone should not preclude the diagnosis of ALK-positive ALCL, underscoring the importance of integrated histopathological and molecular evaluation in diagnostically challenging cases. Meanwhile, it provides a basis for optimizing the diagnostic process of clinically suspected cases.
Keywords
How to cite this article: Wang W, Sui X, Yu G. Does CD30 loss preclude the diagnosis of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma? Insights from a rare case. CytoJournal. 2026;23:45. doi: 10.25259/Cytojournal_148_2025
INTRODUCTION
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is a distinct subtype of mature T-cell lymphoma, typically characterized by diffuse and strong CD30 expression and recurrent ALK gene rearrangements, most commonly nucleophosmin 1 ALK (NPM1-ALK) fusion.[1] CD30 is not only a key diagnostic hallmark but also an important therapeutic target, particularly with the advent of anti-CD30-directed therapies such as brentuximab vedotin.
Although CD30 expression is considered a defining feature of ALCL, rare cases with partial or complete loss of CD30 expression have been reported and may pose significant diagnostic challenges, especially in small biopsy specimens. Such cases raise critical questions regarding the diagnostic utility of CD30 negativity and the underlying mechanisms driving this phenotypic divergence. We report a rare case of ALK+ ALCL exhibiting two distinct tumor cell populations within the same lesion: One showing classic CD30-positive morphology and immunophenotype, and the other demonstrating complete loss of CD30 expression. A comparative analysis of histological, immunophenotypic, and molecular features between these two components provides insight into the heterogeneity and pathogenesis of ALCL and emphasizes the need for comprehensive diagnostic evaluation in atypical presentations.
CASE REPORT
A 45-year-old male presented with a 2-month history of a rapidly progressive mass on the upper back between the scapulae, accompanied by local pain and erythema. Physical examination revealed a 10 × 15 cm lesion that was slightly elevated above the skin surface, erythematous, tender, soft to moderately firm on palpation, and poorly mobile. Complete blood count: White blood cell count: 12.03 × 109/L, neutrophils: 8.17 × 109/L, platelets: 356 × 109/L, hemoglobin: 121 g/L. Positron emission tomography/computed tomography revealed a large hypermetabolic soft tissue mass in the upper back, accompanied by multiple hypermetabolic lymph nodes in the cervical and thoracic regions [Figure 1a-d]. The maximum standardized uptake value of the involved lesions reached ~36.5, indicating high metabolic activity. A bone marrow biopsy and peripheral blood smear were performed, which showed no evidence of tumor infiltration. The patient was referred to another hospital for further treatment after diagnosis. He received six cycles of brentuximab vedotin (anti-CD30 monoclonal antibody) combined with cyclophosphamide, doxorubicin, and prednisone chemotherapy regimen as first-line treatment. Detailed information regarding these medications is provided in the Supplementary Material. At the 15-month follow-up after initial diagnosis, the patient remained alive.

Pathological findings
The mass exhibited two distinct cellular morphologies microscopically, designated PART1 and PART2, respectively [Figure 2a]. PART1 consisted of diffusely proliferating small to medium-sized tumor lymphocytes with large, darkly stained, round nuclei and basophilic cytoplasm [Figure 2b]. In contrast to the classic morphology of ALK+ ALCL observed in PART1, PART2 displayed uniformly cytoplasmic, translucent tumor cells with round, darkly stained nuclei, and abundant cytoplasm [Figure 2c].

A comprehensive immunohistochemical panel was performed to characterize the two tumor components. Detailed immunohistochemical staining procedures are provided in the Supplementary Material, and information on the primary antibodies and the secondary antibody/detection system has been summarized in Supplementary Tables 1 and 2, respectively. The immunohistochemical profiles of the two components also differed. Regarding CD30 expression, the overview [Figure 2d] showed that Part 1 was strongly positive [Figure 2e], while Part 2 was negative [Figure 2f]. As for ALK expression, the overview [Figure 2g] demonstrated that Part 1 exhibited both nuclear and cytoplasmic positivity [Figure 2h], whereas Part 2 showed only nuclear positivity [Figure 2i].In addition, Part 1 was partially positive for multiple myeloma oncogene 1 (MUM1) [Figure 3a] and MYC proto-oncogene (MYC) [Figure 3b], with a Ki-67 proliferation index of ~90% [Figure 3c]. In contrast, Part 2 was negative for MUM1 [Figure 3d] and MYC proto-oncogene [Figure 3e], with a Ki-67 proliferation index of around 10% [Figure 3c]. The remaining immunostains were relatively consistent, which were positive for CD2, GrB, TIA-1, CD3, Vimentin, CD4 (weak positive), CD7 (partial positive), CD5 (partial positive), P63 (weak partial positive) and negative for CD8, PAX5, CD20, CD21, cytokeratin, S-100, leukocyte common antigen (LCA), CD34, desmin, smooth muscle actin, CD31, ERG, Bcl2. In situ hybridization for Epstein-Barr virus-encoded RNA was negative. Flow cytometry revealed a reduced proportion of lymphocytes, an increased proportion of natural killer cells, and no significant abnormalities in phenotype; B precursor cells and plasma cells were observed. Fluorescence in situ hybridization analysis using an ALK break-apart probe showed the presence of rearranged ALK genes in ~13% of the cells [Figure 3f].

Molecular analysis
Microscopically, both CD30 and ALK manifest distinctive expressions across the subpopulations of this tumor, exhibiting well-defined demarcations. To investigate this phenomenon, we conducted a genetic sequencing analysis and a comparative study of these two subpopulations and found the following differences: the NPM1-ALK gene fusion, with an allele frequency (AF) of 16.31% in PART1 and 11.32% in PART2, and the notch receptor 1 (NOTCH1) single-nucleotide variant (SNV) variant, with a content of c.5422 G>A, showed 49.85% AF in PART1 and 46.93% in PART2; in addition, PART2 exhibited a deletion mutation at position c.179_182 of PR/SET domain 1 (PRDM1), with an AF of 2.08%, and the excision repair cross-complementation group 1 (ERCC1) SNV variant, which reads c.329A>T, with an AF of 2.08%, which were not present in PART1. Furthermore, PART1, in comparison to PART2, exhibited distinct amplifications of the MYC and BCL2L1 genes, with a multiplicity of 1.53 and 3.5 [Table 1].
| Gene | Variant type | PART 1 | PART 2 | ||
|---|---|---|---|---|---|
| Contents | AF/Multiplicity (%) | Contents | AF/Multiplicity (%) | ||
| NPM1-ALK | Fusion | chr5:170818803-chr2:29446394 | 16.31 | chr5:170818803-chr2:29446394 | 11.32 |
| NOTCH1 | SNV | c. 5422G>A | 49.85 | c. 5422G>A | 46.93 |
| PRDM1 | Deletion | - | - | c. 179_182del | 2.08 |
| ERCC1 | SNV | - | - | c. 329A>T | 2.08 |
| MYC | CNV | MYC amplification | 1.53 | - | - |
| BCL2L1 | CNV | BCL2L1 amplification | 3.5 | - | - |
AF: Allele frequency, SNV: Single nucleotide variant, CNV: Copy number variation; NPM1: Nucleophosmin 1, ALK: Anaplastic lymphoma kinase, NOTCH1: Notch receptor 1, PRDM1: PR/SET domain 1, ERCC1: Excision repair cross-complementation group 1, MYC: MYC proto-oncogene, BCL2L1: BCL2-like 1.
DISCUSSION
The NPM1-ALK gene fusion, identified in both PART1 and PART2, plays a crucial role in the pathogenesis of ALK+ ALCL, acting as a constitutively active tyrosine kinase that promotes tumorigenesis through multiple downstream pathways, including Janus kinase-signal transducer and activator of transcription, phosphoinositide 3-kinase-AKT serine/threonine kinase, and mitogen-activated protein kinase signaling.[1] The consistent presence of this fusion in both subpopulations confirms their common clonal origin, supporting the notion that the CD30-negative PART2 is a divergent subclone derived from the CD30-positive parental clone. Similarly, NOTCH1 mutations, observed in both components, have been reported in ALCL and are associated with tumor cell proliferation, survival, and differentiation by regulating downstream targets involved in T-cell development.[2] The high AF of NOTCH1 mutation in both subpopulations suggests that this alteration occurred early in tumorigenesis and was retained during clonal divergence.
The restriction of ALK immunoreactivity to the nucleus in the small neoplastic cells observed in PART2, although unusual, has been reported in small cell-predominant ALK-positive ALCL. Falini et al.[3] suggested that although the NPM1-ALK fusion protein can accumulate within the nucleus, its oncogenic signaling activity is believed to occur predominantly in the cytoplasm. In small neoplastic cells, the cytoplasmic volume is limited, and cytoplasmic NPM1-ALK expression may be intrinsically low. Such low-level cytoplasmic expression may be sufficient at the molecular level to activate oncogenic signaling pathways yet remain below the detection threshold of routine immunohistochemistry, particularly after formalin fixation and paraffin embedding. Consequently, an apparently nuclear-restricted staining pattern does not necessarily indicate true absence of cytoplasmic ALK expression.
In contrast, a PRDM1 deletion and an ERCC1 SNV were exclusively detected in PART2 at low allele frequencies (both 2.08%). While the significance of these subclonal mutations remains uncertain, PRDM1 deletions have previously been reported to occur more frequently in ALK-negative large cell lymphoma.[4] The ERCC1 gene encodes a subunit of ERCC1-xeroderma pigmentosum group F nuclease, an enzyme that plays an important role in the repair of DNA damage and the maintenance of genome stability.[5] However, there are currently no reports of mutations of this gene in ALCL. Given their low abundance, these alterations are most consistent with subclonal events and may also reflect background sequencing noise. At present, there is insufficient evidence to support a direct causal role of these low-frequency alterations in driving the CD30-negative phenotype, and they are more likely to represent incidental passenger events. Nevertheless, their presence underscores the genetic complexity and intratumoral heterogeneity of this case; their potential biological relevance warrants further investigation.
The amplification of MYC and BCL2L1 observed in PART1, but absent in PART2, may correlate with the higher proliferative index in this region. MYC is a well-known protooncogene that acts as a non-linear amplifier in lymphomas by enhancing the expression of other active genes, thereby promoting aberrant cell proliferation.[6] Previous studies have suggested that the NPM1-ALK fusion gene protects MYC from degradation in ALCL.[7] In our case, MYC protein expression was higher in PART1 compared to PART2, consistent with the observed genetic differences. Although the observed MYC amplification is modest, our immunohistochemical findings suggest differential protein expression, possibly driven by both genetic and post-transcriptional mechanisms. Likewise, BCL2L1 encodes an anti-apoptotic protein, BCLXL, and its amplification has been implicated in resistance to cell death in other lymphoma subtypes.[8] While MYC and BCL gene amplification are frequently observed in B-cell lymphomas and have been documented to have a minimal impact on prognosis. However, these amplifications have not been reported in ALCL yet. The potential for these two amplifications to synergize and affect the expression of other proteins in ALCL remains to be investigated through further research. In this context, co-amplification of MYC and BCL2L1 may exert a cooperative effect by coupling increased proliferative drive with suppression of MYC-induced apoptotic stress, thereby creating a biologically permissive environment for sustained tumor growth. Although this association remains correlative in the setting of a single case, this synergistic mechanism is biologically plausible and may help explain the higher proliferative activity observed in PART1. Further studies are required to clarify the functional significance of these alterations in ALCL.
Regarding the loss of CD30 expression, it has been demonstrated that CD30 expression is dependent on the activity of the NPM1-ALK fusion gene.[9] Additional regulatory factors, such as MUM1 (interferon regulatory factor 4), which participates in a positive feedback loop with CD30 through nuclear factor kappa-light-chain-enhancer of activated B cells signaling, may further modulate CD30 expression.[10] In this case, MUM1 expression was observed in PART1 but absent in PART2, further supporting the idea of differential transcriptional environments between the two regions. Although the frequency of NPM1-ALK rearrangement was slightly lower in PART2, and MYC amplification was absent, the exact mechanism underlying CD30 loss remains unclear. Given the involvement of multiple transcriptional, epigenetic, and microenvironmental factors in CD30 regulation, this discrepancy should be interpreted as one of several possible contributing factors that warrant further investigation.
From a clinical perspective, intratumoral heterogeneity in CD30 expression may have important therapeutic implications. Recent reports have described decreased CD30 expression and disease progression in ALCL patients treated with brentuximab vedotin, suggesting that CD30 loss may contribute to therapeutic resistance. Although the patient in this case has not shown evidence of disease relapse to date, the presence of a CD30-negative subpopulation highlights the importance of close clinical follow-up and suggests that monitoring CD30 expression during treatment may be warranted.
SUMMARY
We report a rare case of ALK+ ALCL with two distinct subpopulations differing in morphology, immunophenotype, and molecular features, particularly CD30 expression status. The comparative genetic analysis reveals the common clonal origin of the two subpopulations and identifies key molecular differences that may underlie their phenotypic divergence. Our findings confirm that CD30 negativity alone does not preclude the diagnosis of ALK+ ALCL, highlighting the need for integrated histopathological and molecular evaluation in diagnostically challenging cases. Furthermore, the intratumoral heterogeneity observed in this case has important implications for CD30-targeted therapy, emphasizing the necessity of close follow-up and potential CD30 expression monitoring. This case expands our understanding of the genetic complexity and phenotypic heterogeneity of ALCL and provides a basis for optimizing the diagnosis and treatment of similar cases.
AVAILABILITY OF DATA AND MATERIALS
The data underlying the findings of this study are available from the corresponding author upon reasonable request.
ABBREVIATIONS
AKT: AKT serine/threonine kinase
ALK: Anaplastic lymphoma kinase
ALCL: Anaplastic large cell lymphoma
AF: Allele frequency
BCL2L1: BCL2-like 1
BV: Brentuximab vedotin
CHP: Cyclophosphamide, doxorubicin, and prednisone
CK: Cytokeratin
CNV: Copy number variation
EBV: Epstein–Barr virus
EBER: Epstein–Barr virus-encoded small RNA
ERCC1: Excision repair cross-complementation group 1
FISH: Fluorescence in situ hybridization
IRF4: Interferon regulatory factor 4
JAK: Janus kinase
LCA: Leukocyte common antigen
MAPK: Mitogen-activated protein kinase
MUM1: Multiple myeloma oncogene 1
MYC: MYC proto-oncogene
NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells;
NK: Natural killer
NPM1: Nucleophosmin 1
NOTCH1: Notch receptor 1
PET-CT: Positron emission tomography–computed tomography
PI3K: Phosphoinositide 3-kinase
PRDM1: PR/SET domain 1
SMA: Smooth muscle actin
SNV: Single-nucleotide variant
STAT: Signal transducer and activator of transcription
SUVmax: Maximum standardized uptake value
Vim: Vimentin
AUTHOR CONTRIBUTIONS
XS: Revised the manuscript critically for important intellectual content. XS and GY: Contributed to the conception and design of the study and were involved in data acquisition; WW: Performed data analysis and drafted the manuscript; GY: Critically revised the manuscript for important intellectual content. All authors read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work. All authors meet ICMJE authorship requirements.
ACKNOWLEDGMENT
Not applicable.
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
This study is a retrospective analysis based on previously collected, anonymized clinical data from the patient’s medical records. No identifiable personal information was accessed during the research. Written informed consent was obtained from the patient for the publication of this case report. The study was approved by the Yantai Yuhuangding Hospital (Approval No. K2026-210).
CONFLICTS OF INTEREST
Given his role as one of the editorial board members of Cytojournal, Guohua Yu had no involvement in the peer review of this article and has no access to information regarding its peer review.
EDITORIAL/PEER REVIEW
To ensure the integrity and highest quality of CytoJournal publications, the review process of this manuscript was conducted under a double-blind model (authors are blinded for reviewers and vice versa) through an automatic online system.
FUNDING: This project is supported by the general project ZR2022MH297 of the Shandong Natural Science Foundation.
References
- Mechanism for the activation of the anaplastic lymphoma kinase receptor. Nature. 2021;600:153-7.
- [CrossRef] [PubMed] [Google Scholar]
- Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica. 2021;106:1693-704.
- [CrossRef] [PubMed] [Google Scholar]
- ALK expression defines a distinct group of t/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol. 1998;153:875-86.
- [CrossRef] [PubMed] [Google Scholar]
- PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood. 2013;122:2683-93.
- [CrossRef] [PubMed] [Google Scholar]
- The ERCC1 and ERCC4 (XPF) genes and gene products. Gene. 2015;569:153-61.
- [CrossRef] [PubMed] [Google Scholar]
- Nuclear NPM-ALK protects myc from proteosomal degradation and contributes to high protein expression in cancer stem-like cells in ALK-positive anaplastic large cell lymphoma. Blood. 2022;140(Suppl 1):6452.
- [CrossRef] [Google Scholar]
- Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2. Cell Res. 2017;27:329-51.
- [CrossRef] [PubMed] [Google Scholar]
- ALK-transformed mature T lymphocytes restore early thymus progenitor features. J Clin Invest. 2020;130:6395-408.
- [CrossRef] [PubMed] [Google Scholar]
- The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-kB positive feedback loop in peripheral T-cell lymphoma. Blood. 2015;125:3118-27.
- [CrossRef] [PubMed] [Google Scholar]


